Trial Profile

Dose Ranging Study of Tolperisone in Acute Muscle Spasm of the Back

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolperisone (Primary)
Indications Back pain; Spasm
Focus Therapeutic Use
Acronyms STAR
Sponsors Neurana Pharmaceuticals

Most Recent Events

23 Nov 2020 According to a Neurana Pharmaceuticals media release, Srinivas Nalamachu, (M.D., Adjunct Associate Professor, Kansas City University of Medicine and Biosciences) is the lead author.
23 Nov 2020 According to a Neurana Pharmaceuticals media release, results from this dose-ranging Phase 2 study were published in the Journal of Pain Research.
23 Nov 2020 Results presented in a Neurana Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com